152 related articles for article (PubMed ID: 18000194)
1. Bone densitometry and treatment for osteoporosis in older men.
Ito K
JAMA; 2007 Nov; 298(18):2136-7; author reply 2137. PubMed ID: 18000194
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
Schousboe JT; Taylor BC; Fink HA; Kane RL; Cummings SR; Orwoll ES; Melton LJ; Bauer DC; Ensrud KE
JAMA; 2007 Aug; 298(6):629-37. PubMed ID: 17684185
[TBL] [Abstract][Full Text] [Related]
3. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland.
Schwenkglenks M; Lippuner K
Osteoporos Int; 2007 Nov; 18(11):1481-91. PubMed ID: 17530156
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women.
Mueller D; Gandjour A
Value Health; 2009; 12(8):1106-17. PubMed ID: 19706151
[TBL] [Abstract][Full Text] [Related]
5. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
[TBL] [Abstract][Full Text] [Related]
6. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.
Kingkaew P; Maleewong U; Ngarmukos C; Teerawattananon Y
Value Health; 2012; 15(1 Suppl):S20-8. PubMed ID: 22265062
[TBL] [Abstract][Full Text] [Related]
7. [Cost effective osteoporosis therapy. Alendronate is also immediately available as a generic drug].
MMW Fortschr Med; 2005 Dec; 147(49-50):74-5. PubMed ID: 16401016
[No Abstract] [Full Text] [Related]
8. A fractured service: will NOGG mend it?
Bayly J
Br J Gen Pract; 2009 May; 59(562):371-2. PubMed ID: 19401020
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
Jansen JP; Gaugris S; Bergman G; Sen SS
Curr Med Res Opin; 2008 Mar; 24(3):671-84. PubMed ID: 18221588
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence.
Hiligsmann M; Gathon HJ; Bruyère O; Ethgen O; Rabenda V; Reginster JY
Value Health; 2010; 13(4):394-401. PubMed ID: 20102558
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women.
Mueller D; Gandjour A
Appl Health Econ Health Policy; 2008; 6(2-3):113-35. PubMed ID: 19231905
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of osteoporosis interventions for 'incidental' vertebral fractures.
Majumdar SR; Lier DA; McAlister FA; Rowe BH; Siminoski K; Hanley DA; Russell AS; Johnson JA
Am J Med; 2013 Feb; 126(2):169.e9-17. PubMed ID: 23331449
[TBL] [Abstract][Full Text] [Related]
13. The population of health economic models is critical.
Stevenson M
Bone; 2008 Jul; 43(1):214. PubMed ID: 18411076
[No Abstract] [Full Text] [Related]
14. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis.
Hiligsmann M; Ethgen O; Bruyère O; Richy F; Gathon HJ; Reginster JY
Value Health; 2009; 12(5):687-96. PubMed ID: 19508659
[TBL] [Abstract][Full Text] [Related]
15. Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment.
Nayak S; Roberts MS; Greenspan SL
PLoS One; 2012; 7(3):e32879. PubMed ID: 22427903
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
[TBL] [Abstract][Full Text] [Related]
17. Bridging the osteoporosis treatment gap: performance and cost-effectiveness of a fracture liaison service.
Yates CJ; Chauchard MA; Liew D; Bucknill A; Wark JD
J Clin Densitom; 2015; 18(2):150-6. PubMed ID: 25797867
[TBL] [Abstract][Full Text] [Related]
18. [Practical guidelines for the management of osteoporosis--evidence-based and cost-effective].
Bartl R
Dtsch Med Wochenschr; 2007 May; 132(18):995-9. PubMed ID: 17457784
[No Abstract] [Full Text] [Related]
19. Screening for osteoporosis in postmenopausal women with breast cancer receiving aromatase inhibitors: less is more?
Dhesy-Thind SK
J Clin Oncol; 2012 May; 30(13):1408-10. PubMed ID: 22370320
[No Abstract] [Full Text] [Related]
20. Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
Blouin J; Dragomir A; Fredette M; Ste-Marie LG; Fernandes JC; Perreault S
Osteoporos Int; 2009 Sep; 20(9):1571-81. PubMed ID: 19107385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
